The Precision Medicine Stock That's Revolutionizing Cancer Treatment
Foundation Medicine's (NASDAQ: FMI) genetic screening tests are leading the way in discovering what medicines will work best in cancer patients based on their DNA. As more specialized drugs targeting specific genetic mutations launch, greater reliance on genetic screening will be key to accelerating their use and validating their efficacy. The company's tests are already generating significant sales growth, but it's only early innings in this shift in cancer care. Here's what you need to know before adding this stock to your portfolio.
Already, there are more than 70 FDA approved therapies that can be better matched to patients by genetic testing and thousands of clinical trials are ongoing that significantly expand the need for genetic insight.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
